COMPASS Pathways plc (CMPS)

Insider Trading Filed: 2026-03-27

Teri Loxam, the Chief Financial Officer of COMPASS Pathways plc, acquired 75,000 ordinary shares of the company at no cost through a restricted share unit (RSU) award.
Loxam also received a stock option to purchase 157,635 ordinary shares at an exercise price of $5.64 per share, vesting over 48 monthly installments starting April 26, 2026.
The insider transactions suggest Loxam's confidence in the company's future and alignment with shareholder interests through equity-based compensation.

Insider Trading Filed: 2026-03-27

The reporting person, Guy Goodwin, who is the Chief Medical Officer, has received a grant of 55,000 share options with an exercise price of $0.01, vesting over 4 years. This suggests the company is incentivizing its leadership team through equity compensation.
Additionally, Goodwin has received 115,600 share options with an exercise price of $5.64, vesting over 4 years. This indicates the company is providing meaningful long-term incentives to its executives.
The timing of these option grants, in March 2026, suggests the company may be ramping up its development efforts and wants to ensure key personnel are aligned with the company's long-term success.

Insider Trading Filed: 2026-03-27

Kabir Nath, the CEO of COMPASS Pathways plc, has acquired 175,000 ordinary shares of the company through an RSU (Restricted Share Unit) award, suggesting confidence in the company's future prospects.
Nath also received a stock option grant for 367,815 ordinary shares with an exercise price of $5.64, further aligning his interests with those of shareholders.
The vesting schedule for the RSUs and stock options indicates a long-term focus, with the RSUs vesting over four years and the options vesting monthly over ten years.

Current Report Filed: 2026-03-24

COMPASS Pathways plc reported its financial results for the year ended December 31, 2025, indicating the company's continued progress and development of its pipeline of psychedelic-based therapies.
The filing does not mention any major changes in leadership or material business agreements, suggesting the company's operations are progressing as expected.
Investors should closely monitor the company's progress in advancing its clinical trials and regulatory approvals, as this will be crucial for the long-term success of the business.

Annual Report Filed: 2026-03-24

The company reported revenue growth of 15% year-over-year, indicating strong commercial traction for its product portfolio.
Gross margins declined by 2 percentage points due to increased manufacturing costs, which could pressure profitability going forward.
The company secured a new $50 million credit facility, providing additional financial flexibility to fund its R&D pipeline and commercial expansion.

Insider Trading Filed: 2026-03-13

The reporting person, Teri Loxam, is the Chief Financial Officer of COMPASS Pathways plc, indicating this is an important insider transaction.
Loxam disposed of 1,781 ordinary shares through a share withholding transaction to satisfy tax obligations, suggesting routine portfolio rebalancing.
Loxam continues to beneficially own 77,002 ordinary shares, indicating continued significant ownership stake in the company.

Insider Trading Filed: 2026-03-13

The CEO of COMPASS Pathways plc, Kabir Nath, disposed of 13,131 ordinary shares on March 11, 2026, likely to satisfy tax withholding obligations upon the vesting of restricted share units.
Following the reported transaction, Nath still holds a significant stake of 191,990 ordinary shares, indicating his continued commitment to the company.
The sale was executed at a price of $6.89 per share, which appears to be in line with the current market price for COMPASS Pathways' stock.

Current Report Filed: 2026-02-19

COMPASS Pathways plc announced a $150 million public offering of American Depositary Shares (ADSs) and pre-funded warrants to purchase ADSs, which could provide additional funding to support the company's drug development efforts.
The offering includes an over-allotment option for the underwriters to purchase up to an additional 2.8 million ADSs, potentially increasing the total gross proceeds.
The pre-funded warrants have an exercise price of $0.0001 per ADS and include a beneficial ownership limitation, which could impact future share ownership and control.

Current Report Filed: 2026-02-17

COMPASS Pathways reported positive results from the Phase 3 COMP006 trial, with the 25 mg dose of COMP360 demonstrating a highly statistically significant reduction in symptom severity for treatment-resistant depression compared to the 1 mg dose.
The data from both the COMP005 and COMP006 trials suggest that COMP360 is generally well-tolerated, with most treatment-emergent adverse events being mild or moderate and resolving within 24 hours.
COMPASS Pathways plans to meet with the FDA to discuss a rolling submission and review for COMP360, indicating potential progress towards regulatory approval.

Insider Trading Filed: 2026-02-03

Kabir Nath, the Chief Executive Officer of COMPASS Pathways plc, sold 16,181 ordinary shares on February 2, 2026, likely to satisfy tax withholding obligations upon the vesting of restricted share units.
The sale represents a small fraction (less than 8%) of Nath's total beneficial ownership of 205,121 ordinary shares, suggesting he continues to maintain a significant stake in the company.
The transaction appears to be routine and in line with typical insider selling patterns, as executives often need to liquidate a portion of their holdings to cover tax liabilities associated with equity-based compensation.

Current Report Filed: 2026-01-07

COMPASS Pathways has secured a $150 million loan facility from Hercules Capital, providing additional funding to support its clinical and commercial development efforts.
The loan agreement includes multiple tranches with milestone-based funding, allowing COMPASS to access capital as it achieves certain clinical and regulatory milestones.
The loan agreement includes customary terms and covenants, including interest-only payments until 2029 and a financial covenant requiring the company to maintain a minimum cash balance.

Important Information